Login / Signup

Outcomes of treatment with sorafenib in Egyptian patients with hepatocellular carcinoma: a retrospective cohort study.

Yousery NadaNoha RashadMai EissaAya GhonaimKyrillus FaragIslam SaadawiAhmed ShehaMahmoud El GewaityOmar Abdel-Rahman
Published in: Expert review of gastroenterology & hepatology (2017)
Sorafenib use should be limited to patients with Child A, PS 0-1, and low disease burden.
Keyphrases
  • mental health
  • risk factors
  • adipose tissue
  • combination therapy
  • skeletal muscle
  • weight loss
  • glycemic control